{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:14:35Z","timestamp":1789924475862,"version":"4.0.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803442"],"award-info":[{"award-number":["81803442"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703425"],"award-info":[{"award-number":["81703425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.canlet.2019.04.017","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T01:49:23Z","timestamp":1555292963000},"page":"191-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Emerging strategies in cancer therapy combining chemotherapy with immunotherapy"],"prefix":"10.1016","volume":"454","author":[{"given":"Qiuhua","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.04.017_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-018-0389-8","article-title":"Design considerations for early-phase clinical trials of immune-oncology agents","volume":"6","author":"Wages","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2019.04.017_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2019.04.017_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.04.017_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.04.017_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2019.04.017_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib7","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib8","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.04.017_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2019.04.017_bib10","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1210\/jc.2007-0147","article-title":"Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis","volume":"92","author":"Kavvoura","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.04.017_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/eje.0.1500619","article-title":"The emerging role of the CTLA-4 gene in autoimmune endocrinopathies","volume":"150","author":"Vaidya","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.04.017_bib12","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00262-013-1451-5","article-title":"Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models","volume":"62","author":"Jure-Kunkel","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2019.04.017_bib13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.04.017_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2019.04.017_bib16","author":"Clinical trials for NSCLC"},{"key":"10.1016\/j.canlet.2019.04.017_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbiotec.2016.10.022","article-title":"Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation","volume":"240","author":"Razaghi","year":"2016","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.canlet.2019.04.017_bib20","doi-asserted-by":"crossref","first-page":"349575","DOI":"10.1155\/2011\/349575","article-title":"Interferon lambda: a new sword in cancer immunotherapy","volume":"2011","author":"Lasfar","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2019.04.017_bib22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2019.04.017_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2165\/00063030-199707050-00007","article-title":"Aldesleukin (recombinant interleukin-2)","volume":"7","author":"Noble","year":"1997","journal-title":"BioDrugs"},{"key":"10.1016\/j.canlet.2019.04.017_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/CMAR.S33979","article-title":"The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses","volume":"4","author":"Coventry","year":"2012","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib25","first-page":"5981","article-title":"Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy","volume":"10","author":"Heo","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2019.04.017_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8(+) T cell invigoration and polyclonal T cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.04.017_bib27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1089\/jir.2014.0221","article-title":"The potentiation of IFN-gamma and induction of cytotoxic proteins by pegylated IL-10 in human CD8 T cells","volume":"35","author":"Chan","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/intimm\/dxw027","article-title":"The present status and future prospects of peptide-based cancer vaccines","volume":"28","author":"Hirayama","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00534-011-0457-7","article-title":"Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients","volume":"19","author":"Endo","year":"2012","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"10.1016\/j.canlet.2019.04.017_bib32","first-page":"22","article-title":"Engineering CAR-T cells, biomark","volume":"5","author":"Zhang","year":"2017","journal-title":"Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib33","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib34","doi-asserted-by":"crossref","first-page":"62730","DOI":"10.18632\/oncotarget.17528","article-title":"Driving better and safer HER2-specific CARs for cancer therapy","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.04.017_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2019.04.017_bib36","first-page":"1","article-title":"Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances","volume":"5","author":"Simpson","year":"2016","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.canlet.2019.04.017_bib37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/mt.2011.65","article-title":"Thunder and lightning: immunotherapy and oncolytic viruses collide","volume":"19","author":"Melcher","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2019.04.017_bib38","doi-asserted-by":"crossref","first-page":"805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.canlet.2019.04.017_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/bjc.2013.695","article-title":"Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms","volume":"110","author":"Gujar","year":"2014","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2019.04.017_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1871520611313050005","article-title":"Beta-Glucans and their applications in cancer therapy: focus on human studies","volume":"13","author":"Aleem","year":"2013","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.canlet.2019.04.017_bib41","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3892\/mmr.2017.6228","article-title":"Fucoidan modulates cytokine production and migration of THP1derived macrophages via colonystimulating factor1","volume":"15","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2019.04.017_bib42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijbiomac.2018.09.059","article-title":"Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin","volume":"122","author":"Pawar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2019.04.017_bib43","doi-asserted-by":"crossref","first-page":"890178","DOI":"10.1155\/2012\/890178","article-title":"Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects","volume":"2012","author":"Ding","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cellimm.2015.02.003","article-title":"Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer","volume":"294","author":"Zheng","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.04.017_bib46","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.04.017_bib47","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-39406-0_6","article-title":"Immunogenic apoptotic cell death and anticancer immunity","volume":"930","author":"Vandenabeele","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2019.04.017_bib49","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.04.017_bib50","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/0008-5472.CAN-16-2165","article-title":"Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy","volume":"77","author":"Fend","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2019.04.017_bib52","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fimmu.2018.00883","article-title":"Emerging functions of regulatory T cells in tissue homeostasis","volume":"9","author":"Sharma","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib53","doi-asserted-by":"crossref","first-page":"635451","DOI":"10.1155\/2012\/635451","article-title":"Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages","volume":"2012","author":"Tomioka","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib54","doi-asserted-by":"crossref","first-page":"4986797","DOI":"10.1155\/2016\/4986797","article-title":"The crosstalk between myeloid derived suppressor cells and immune cells: to establish immune tolerance in transplantation","volume":"2016","author":"Zhang","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.117.245704","article-title":"Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy","volume":"366","author":"Curry","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.canlet.2019.04.017_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biomaterials.2016.04.010","article-title":"Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy","volume":"96","author":"Sasso","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2019.04.017_bib58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2019.04.017_bib59","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2019.04.017_bib60","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2019.04.017_bib61","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-08-1170","article-title":"Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin","volume":"8","author":"LeBeau","year":"2009","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2019.04.017_bib62","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1021\/nn404083m","article-title":"Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2019.04.017_bib63","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/mp100153r","article-title":"Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach","volume":"7","author":"Roy","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2019.04.017_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aao1736","article-title":"Elimination of established tumors with nanodisc-based combination chemoimmunotherapy","volume":"4","author":"Kuai","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2019.04.017_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib66","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7150\/thno.16684","article-title":"Current multistage drug delivery systems based on the tumor microenvironment","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2019.04.017_bib67","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/472303a","article-title":"Cancer: macrophages limit chemotherapy","volume":"472","author":"De Palma","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.04.017_bib68","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1021\/acs.nanolett.7b01193","article-title":"Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy","volume":"17","author":"Shen","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2019.04.017_bib69","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acsnano.6b02326","article-title":"Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration","volume":"10","author":"Li","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2019.04.017_bib70","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/anie.201800422","article-title":"A Cisplatin-Loaded Immunochemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy","volume":"57","author":"Wang","year":"2018","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.canlet.2019.04.017_bib71","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrc2639","article-title":"Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?","volume":"9","author":"Lob","year":"2009","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2019.04.017_bib72","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2019.04.017_bib73","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1196\/annals.1297.021","article-title":"Interleukin-7: an interleukin for rejuvenating the immune system","volume":"1019","author":"Aspinall","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2019.04.017_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085789","article-title":"Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice","volume":"9","author":"Gou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2019.04.017_bib75","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/14737140.2018.1531707","article-title":"Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies","volume":"18","author":"Matsui","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2019.04.017_bib76","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-14-2142","article-title":"Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death","volume":"21","author":"van der Sluis","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpharm.2013.01.045","article-title":"Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model","volume":"445","author":"Roy","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2019.04.017_bib78","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"Weigelt","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2019.04.017_bib79","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nri3049","article-title":"Homeostatic chemokine receptors and organ-specific metastasis","volume":"11","author":"Zlotnik","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2019.04.017_bib80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10911-011-9217-1","article-title":"TGF-beta signaling in breast cancer cell invasion and bone metastasis","volume":"16","author":"Drabsch","year":"2011","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.canlet.2019.04.017_bib81","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.017_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201802403","article-title":"PD-1 blockade for improving the antitumor efficiency of polymer-doxorubicin nanoprodrug","volume":"14","author":"Gao","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.canlet.2019.04.017_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2015.08.027","article-title":"Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin","volume":"217","author":"Miao","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.canlet.2019.04.017_bib84","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acsnano.7b01522","article-title":"Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles","volume":"11","author":"Hu","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2019.04.017_bib85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/17425255.2015.1028356","article-title":"Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism","volume":"11","author":"Joyce","year":"2015","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.canlet.2019.04.017_bib86","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1535-7163.MCT-16-0454","article-title":"The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects","volume":"16","author":"Ding","year":"2017","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2019.04.017_bib87","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccell.2015.11.002","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"28","author":"Ozdemir","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.04.017_bib88","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer","volume":"165","author":"Wang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.04.017_bib89","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients","volume":"24","author":"Tallon de Lara","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib90","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","article-title":"Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis","volume":"74","author":"Ding","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.017_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1114203","article-title":"Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS","volume":"5","author":"Franzese","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.04.017_bib92","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/onc.2016.225","article-title":"Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer","volume":"36","author":"Chouaib","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2019.04.017_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201801120","article-title":"A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD-1\/PD-L1 axis","volume":"14","author":"Zou","year":"2018","journal-title":"Small"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519302423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519302423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:45:40Z","timestamp":1759592740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519302423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":91,"alternative-id":["S0304383519302423"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.04.017","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging strategies in cancer therapy combining chemotherapy with immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}